Sunday, June 14, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 266 of 1,261

  1. US 11332470

    CXCR4 inhibitors and uses thereof

    X4 Pharmaceuticals, Inc. · Granted May 17, 2022 · Expires May 12, 2042

    granted

  2. US 11331333

    Treatment of aberrant fibroblast proliferation

    The Board of Regents of the University of Texas System · Granted May 17, 2022 · Expires May 12, 2042

    granted

  3. US 11331363

    Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations

    Nature's Sunshine Products, Inc. · Granted May 17, 2022 · Expires May 12, 2042

    granted

  4. AU 2020370603

    Chikungunya virus-like particle vaccine and methods of using the same

    BAVARIAN NORDIC AS [DK] · Granted May 12, 2022 · Expires May 7, 2042

    granted

  5. US 11325916

    Spiropyrrolidine derived antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  6. US 11325973

    Modulation of stimulatory and non-stimulatory myeloid cells

    The Regents of the University of California · Granted May 10, 2022 · Expires May 5, 2042

    granted

  7. US 11324820

    Methods for the treatment of subjects having a hepatitis b virus (HBV) infection

    Alnylam Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  8. US 11325898

    Small molecule inducers of autophagy

    The Board of Regents of the University of Texas System · Granted May 10, 2022 · Expires May 5, 2042

    granted

  9. US 11324734

    Compositions and methods for treating anemia

    Akebia Therapeutics, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  10. US 11324753

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Supernus Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  11. US 11324811

    Optimization of enzyme replacement therapy for treatment of homocystinuria

    The Regents of the University of Colorado, a Body Corporate · Granted May 10, 2022 · Expires May 5, 2042

    granted

  12. US 11324725

    Compositions and methods for the inhibition of pruritus

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 10, 2022 · Expires May 5, 2042

    granted

  13. US 11325978

    Compositions and methods for treating beta-globinopathies

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted May 10, 2022 · Expires May 5, 2042

    granted

  14. US 11324735

    Method of treatment with tradipitant

    VANDA PHARMACEUTICALS INC. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  15. US 11324673

    Cosmetic appearance of skin

    MIRAKI INNOVATION THINK TANK LLC · Granted May 10, 2022 · Expires May 5, 2042

    granted

  16. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Syndax Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  17. US 11325938

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  18. US 11326182

    Compositions for the treatment of disease

    VOYAGER THERAPEUTICS, INC. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  19. US 11326166

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  20. US 11325965

    Single-domain VH H antibodies directed to norovirus GI.1 and GII.4 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 10, 2022 · Expires May 5, 2042

    granted

  21. US 11327083

    Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted May 10, 2022 · Expires May 5, 2042

    granted

  22. US 11325957

    Methods and compositions for reducing the immunogenicity of chimeric notch receptors

    Cell Design Labs, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  23. US 11325936

    Sialidase inhibitors and preparation thereof

    The Regents of the University of California · Granted May 10, 2022 · Expires May 5, 2042

    granted

  24. US 11325907

    Crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and preparation process therefor

    Medshine Discovery Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.